Poseida Therapeutics, Inc.
http://poseida.com/
Questions?
Please contact Sales at: (212) 520-2765 or email PharmaNewsSales@informa.com
Latest From Poseida Therapeutics, Inc.
Takeda Teams With Evozyne On Protein Design For Gene Therapy
Deal Snapshot: Building on a 2021 tie-up between Takeda and the Paragon start-up, Evozyne will seek novel protein sequences for inclusion in gene therapies for rare disease indications.
Still Looking For The Off-The-Shelf Breakthrough, Allogene Touts Myeloma CAR-T Candidate
While a cloud hangs over the future of its CD19-targeting allogeneic candidate, Allogene points to preclinical potential of superior efficacy for ALLO-715.
Asia Deal Watch: Huadong Licenses Two Cancer ADCs From Heidelberg Pharma
German firm’s antibody-drug conjugates use amanitin payload. Plus deals involving Sanwa Kagaku/Crinetics, Takeda/Code Bio, Taro/Alchemee, Mankind/Dr. Reddy’s and more.
Scrip Asks...What Does 2022 Hold For Biopharma? Part 3: Technology And Science
Many industry leaders expect broad progress in the field of RNA technologies following the rapid and successful roll-out of mRNA vaccines against COVID-19 last year. Genetic medicines of various types, emerging platforms for tackling previously “undruggable” targets and the microbiome were among other areas singled out as areas to watch in 2022.
Company Information
- Industry
- Pharmaceuticals
-
In Vitro Diagnostics
- Molecular Diagnostics & Genetic Testing
-
Biotechnology
- Gene Therapy, Cell Therapy
- Nanotechnology, Chips, etc.
-
Drug Discovery Tools
- Genomics-Proteomics
- Other Names / Subsidiaries
-
- Transposagen Biopharmaceuticals, Inc.